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of this study was to assess cervical cancer prevention capacity in select
HIV clinics located in resource-constrained countries.
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were used as appropriate.
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Copyright © 2015 American Society for Colposcopy and Cervical Pand 50% of sites with Pap testing. Cryotherapy and radical hysterectomy
were the most commonly available on-site treatment methods for premalig-
nant and malignant lesions at 29 (74%) and 18 (46%) sites, respectively.
Conclusions: Despite limited resources, most sites surveyed had the ca-
pacity to perform cervical cancer screening and treatment. The existing infra-
structure of HIV clinical and research sites may provide the ideal framework
for scale-up of cervical cancer prevention in resource-constrained countries
with a high burden of cervical dysplasia.
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C ervical cancer is the fourth most common cancer in womenworldwide, and in 2012, there were 528,000 new cases and
266,000 deaths.1 An estimated 85% of new cases and almost 9
of 10 deaths from cervical cancer occur in resource-constrained
regions.2 In sub-Saharan Africa (SSA), there are more than
250millionwomen who are at risk of developing invasive cervical
cancer (ICC).1 The annual incidence of ICC is 50 per 100,000
women in SSA, and in 2012, there were more than 75,000
new cases reported and more than 50,000 women died from
the disease.1,3
Cervical cancer can be prevented through comprehensive
cervical cancer screening and treatment programs. According to
the National Cancer Institute, the annual incidence of ICC in the
United States decreased by 80% after Pap testing was widely
adopted.4 Conversely, the incidence of ICC is expected to rise in
SSA for the next 20 years because of lack of appropriate cervical
cancer prevention services, including high-risk human papilloma-
virus (hrHPV) vaccination programs, the projected doubling of
the population, and the disproportionate burden of HIV in the
region.1 Studies have consistently shown that womenwith HIV in-
fection have higher prevalence and longer persistence of onco-
genic hrHPV subtypes than women without HIV infections.5–7
Because SSA has the highest burden of HIV infection among
women, who are living longer because of the success of HIV treat-
ment, a perfect storm has been created that is anticipated to in-
crease the incidence of ICC.8 However, effective and feasible
screening and treatment approaches need to be developed among
women with HIV infection in this region.
Although Pap testing has been recommended for routine cer-
vical cancer screening in the United States for more than 50 years,
in resource-constrained settings, it is not feasible because of high
cost and the need for cytology services, well trained experienced
personnel, internal and external control mechanisms, and multiple
clinic visits for the patients. Some screening guidelines have in-
corporated hrHPV testing (using either molecular biomarkers
such as DNA and RNA or oncoproteins) into the screening pro-
cess, which has shown high sensitivity.9–11 Although the cost of
hrHPV testing is decreasing, it may still be too costly in some
settings. As a result, many resource-constrained settings have fo-
cused on service delivery models using alternatives to the Pap test2016 31
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(VIA) or Lugol solution (VILI) with same-day cryotherapy in
the see-and-treat approach. Although there is some controversy
around the impact of VIA on reducing ICC incidence and mortal-
ity, it is a cost-effective and practical tool that has been embraced
by theWorld Health Organization for implementation in resource-
constrained settings.12–15
Furthermore, treatment algorithms for cervical dysplasia and
cancer vary from region to region and the management of ICC is a
major challenge due to the lack of treatment options. Recently,
there have been discussions about the potential to expand existing
cervical cancer prevention programs; however, the current in-
frastructure is not well defined.16 The aim of this study is to
describe the current capacity of cervical cancer prevention pro-
grams affiliated with NIH-funded HIV/AIDS networks that are
located in SSA in anticipation of the need-based expansion of
these programs.METHODS
This was a cross-sectional survey of SSA sites affiliated with
the following 4 NIH-funded HIV/AIDS networks: Centers for
AIDS Research (CFAR), International Epidemiologic Databases
to Evaluate AIDS (IeDEA), AIDS Clinical Trials Group (ACTG),
and the AIDSMalignancy Consortium (AMC). However, because
all responding AMC sites were also ACTG sites, for the purpose
of this analysis, they are reported as ACTG sites. Other sites with
more than 1 affiliation were categorized on the basis of the net-
work that they listed on the survey. Although CFAR, ACTG,
and AMC are large innovative HIV/AIDS research networks that
support clinical trials, the IeDEA network collects data generated
during the course of routine carewithin HIV clinics and uses these
data to answer operational and outcomes questions related to anti-
retroviral rollout. The survey included questions about availability
of cervical cancer screening, either on-site or through referrals,
availability of treatment for premalignant and malignant lesions,
and available personnel (see Table 1). Respondents were asked
to describe their site and were able to select more than 1 option.
Surveys were emailed to the affiliated sites and completed by a
site representative between February and December 2013. ForTABLE 1. Survey Questions
1. What type of clinic is your program? (multiple choice: antenatal clinic
clinic, other; more than one answer may be appropriate)
2. Is cervical cancer screening available to your patients (either on site or
3. If cervical cancer screening is available on site:
Does your program screen women with HIV infection? (Yes, No)
Does your program screen women without HIV infection? (Yes, No)
Does your program maintain electronic records on women screened? (Y
Cervical cancer screening is performed by: (multiple choice: clinical o
may be appropriate)
The method(s) used for cervical cancer screening are: (multiple choice:
Treatments available for premalignant lesions and cervical cancer: (m
radiation therapy, chemotherapy, other; more than 1 answer may be
Patients are referred to our facility for cervical cancer screening (Yes, N
Patients are referred from: (multiple choice: antenatal clinic, clinical res
4. If cervical cancer screening is available at referral site:
Distance to referral site
Surveys were emailed to the affiliated sites and completed by a site represen
VIA indicates visual inspection with acetic acid; HPV, human papillomaviru
excision procedure.
32
Copyright © 2015 American Society for Colposcopy and Cervical Pathe IeDEA sites, this study was considered part of the parent study,
which received approval from the institutional review boards pre-
viously. For the other sites, the study was exempt from institu-
tional review board review because it was considered nonhuman
subjects research.
Statistical Methods
The proportion of sites with screening and/or treatment, per-
sonnel, and methods of screening and/or treatment were calcu-
lated. Descriptive and comparative statistics were performed
using SPSS v.22.0. The Pearson χ2 test or Fisher exact test was
used for categorical variables, as appropriate.
RESULTS
Fifty-one (65%) of 78 sites that were invited to participate
completed the survey (see Figure 1). Among the 27 nonres-
ponding sites, 19 (70.4%) were colocated in the same country
as 1 or more responding sites with 16 (59%) colocated in the
same city. Only 8 (29.6%) of the nonresponding sites, rep-
resenting 6 countries (Benin, Mali, Ethiopia, Ghana, Congo, and
Mozambique), were located in countries fromwhich no responses
were received. Most respondents were represented by IeDEA-
affiliated HIV clinics (n = 27 [53%]), followed by CFAR (n =
14 [27%]) and ACTG (n = 10 [20%]).
Clinic Type, Screening Access, Personnel
Thirty-three respondents (65%) described their site as a clin-
ical research setting and 34 (67%) described their site as an HIV
care and treatment clinic. Additional responses included 12 family
planning clinics (24%), 9 antenatal care clinics (18%), 7 primary
care clinics (14%), and 5 other (10%; tertiary care hospital, sexu-
ally transmitted disease clinic, or cancer center).
Of the 49 sites (96%) that had access to cervical cancer
screening (see Table 2), 39 (80%) had screening services on-site.
Electronic medical records were used at 17 sites (44%) with on-
site screening. Sites in Central Africa were less likely to have
screening on-site compared with the other regions (4 [67%] vs
8 [18%]; p = .02). Specifically, none of the Burundi or Rwanda
sites reported on-site screening. In East Africa, 5 (71%) of the 7, clinical research site, family planning, HIV care site, primary care
via referral)? (Yes, No)
es, No)
fficer, nurse, lay health worker, physician, other; more than 1 answer
Pap, VIA, HPV DNA, VILI; more than 1 answer may be appropriate)
ultiple choice: cryotherapy, conization, LEEP, radical hysterectomy,
appropriate)
o)
earch site, family planning, HIV care site, primary care clinic, other)
tative. Some questions permitted more than 1 answer.
s; VILI, visual inspection with Lugol solution; LEEP, loop electrosurgical
© 2015, American Society for Colposcopy and Cervical Pathology
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FIGURE 1. Location of Responding Sites.
Journal of Lower Genital Tract Disease • Volume 20, Number 1, January 2016 SSA Cervical Cancer Prevention CapacityUgandan sites did not have on-site screening and 2 of these sites
did not have access to screening services elsewhere.
For the 39 sites providing on-site screening, nurses per-
formed screening at 32 sites (82%), including 10 sites (26%) that
relied on nurses exclusively. Physicians provided screening at 25
sites (64%), including 6 sites (24%) that relied on physicians ex-
clusively. Clinical officers provided screening at 11 sites (28%),
and none of these sites relied on clinical officers exclusively.
The remainder of the sites reported a combination of providers, in-
cluding 1 site that reported the availability of lay health workers.© 2015, American Society for Colposcopy and Cervical Pathology
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Visual inspection with acetic acid was the most commonly
reported screening method, which was available at 31 sites
(79%). Eleven (35%) of these 31 sites used VIA as the sole screen-
ing method. Visual inspection with Lugol solution was reported
less commonly at 11 sites (28%). Pap testing was the second most
commonly reported screening method, which was used at 26 sites
(67%). Four (15%) of these 26 sites used Pap testing as the sole
screening method. High-risk HPV testing was available at 13 sites33
athology. Unauthorized reproduction of this article is prohibited.
TABLE 2. Screening Method by Country
Site (by region and country) No. sites
No. on-site
screening programs
Screening method No. sites with electronic
medical recordsPap VIA VILI HPV Colpo/bx
Central Africa (n = 6)
Burundi 3 0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Cameroon 2 2 2 (100) 0 (0) 0 (0) 1 (50) 0 (0) 0 (0)
Rwanda 1 0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
East Africa (n = 18)
Kenya 6 6 5 (83) 6 (100) 2 (33) 3 (50) 0 (0) 5 (83)
Tanzania 5 5 1 (20) 5 (100) 1 (20) 1 (20) 0 (0) 0 (0)
Uganda 7 2 1 (50) 2 (100) 1 (50) 0 (0) 0 (0) 0 (0)
Southern Africa (n = 19)
Botswana 2 2 2 (100) 1 (50) 1 (50) 1 (50) 1 (50) 1 (50)
Lesotho 1 1 1 (100) 1 (100) 0 (0) 0 (0) 0 (0) 1 (100)
Malawi 7 7 3 (43) 7 (100) 2 (29) 2 (29) 1 (14) 1 (14)
South Africa 5 4 4 (100) 2 (50) 1 (25) 2 (50) 2 (50) 3 (75)
Zambia 2 2 0 (0) 2 (100) 0 (0) 0 (0) 0 (0) 2 (100)
Zimbabwe 2 2 1 (50) 2 (100) 0 (0) 0 (0) 1 (50) 2 (100)
West Africa (n = 8)
Burkina Faso 1 1 1 (100) 1 (100) 1 (100) 1 (100) 0 (0) 1 (100)
Côte d'Ivoire 2 1 1 (100) 1 (100) 1 (100) 0 (0) 0 (0) 0 (0)
Nigeria 2 2 2 (100) 1 (50) 1 (50) 1 (50) 0 (0) 1 (50)
Senegal 2 1 1 (100) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0)
Togo 1 1 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 51 39 26 (67) 31 (79) 11 (28) 13 (33) 5 (13) 17 (44)
Data are presented as n (%).
Denominator is the number of on-site screening programs.
VIA indicates visual inspection with acetic acid; VILI, visual inspection with Lugol solution; HPV, human papilloma virus DNA test; colpo/bx, colpos-
copy ± biopsy.
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sole screening method. Most sites (62%) reported the availability
of multiple screening methods. High-risk HPV testing was avail-
able at 29% of sites with VIA or VILI and 50% of sites with
Pap testing. Colposcopy was only available at sites that offered
Pap testing. Of the 26 sites with Pap testing, 5 (19%) had colpos-
copy and 4 (15%) had colposcopy with biopsy services. Sites with
on-site colposcopy and biopsy services were more likely to be lo-
cated in Southern Africa compared with other regions in SSA (5
[28%] vs 0 [0%], p = .02).
Most sites that offered on-site screening also had treatment
available (n = 36 [92%]) and some had multiple treatment options
available. Cryotherapy was the most commonly reported method
available to treat premalignant lesions, which was used at 29 sites
(74%). Excisional procedures, such as a loop electrosurgical exci-
sion procedure (LEEP) and cold-knife cone biopsy, were offered
at 23 (59%) and 12 (31%) sites, respectively. Of the sites that of-
fered cryotherapy, 24 (77%) reported having either LEEP or
cold-knife cone biopsy available, if needed. Radical or extended
hysterectomy was the most commonly reported method available
to treat ICC, which was used at 18 sites (46%). Fewer sites had
chemotherapy or radiation therapy at 10 (26%) and 6 (15%), re-
spectively. Of the sites that offered radical or extended hysterec-
tomy, 9 (50%) had chemotherapy, 5 (28%) had radiation therapy,
and 4 (22%) had both chemotherapy and radiation available.
Nearly 37 sites (95%) reported on-site cervical cancer pre-
vention programs for women with HIV infection, and 8 (22%)
of these sites restricted services to women with HIV infection
alone (see Table 3). There were no significant differences between34
Copyright © 2015 American Society for Colposcopy and Cervical Pathe screening and treatment modalities available at the sites that
offered services to women with HIV infection compared with
those that offered services to both HIV infected and uninfected
(data not shown).
Referral Center Designation and Access
Thirty sites (59%) served as a referral center for cervical can-
cer screening. Of these, 26 (87%) received referrals from other
HIV care and treatment programs and 20 (67%) received referrals
from primary care clinics. The remainder of the referrals to the in-
dividual programs originated from family planning clinics 17
(60%), clinical research sites 17 (57%), antenatal care clinics 15
(50%), and other clinic types 8 (27%). Sites were queried on the
access to referral centers for cervical cancer screening that was
not available at their clinic. For the 12 sites (24%) that did not have
on-site screening, 10 (83%) of their referral sites were located
within the same facility or less than 10 km away, and 2 sites
(17%) did not have access to a referral clinic.
DISCUSSION
Most sites affiliated with an NIH-funded HIV/AIDS network
in our study had on-site cervical cancer screening programs, and
almost all had access to screening, even if screening was not avail-
able on-site. Some of these sites also served as referral centers
from other treatment programs. These data show that the infra-
structure for cervical cancer screening and linkages between
clinics have been established in many urban areas; however, there
remain a few challenges.© 2015, American Society for Colposcopy and Cervical Pathology
thology. Unauthorized reproduction of this article is prohibited.
TABLE 3. SitesWithOn-Site Screening and Treatment Available
by HIV Statusa, b
HIV infected
(n = 37)
HIVuninfected
(n = 29)
Screening
VIA 29 (78) 24 (83)
Pap 25 (68) 19 (66)
HPV DNA 13 (35) 10 (34)
VILI 10 (27) 9 (31)
Colposcopy ± biopsy 4 (11) 3 (10)
Treatment
None 3 (8) 1 (3)
Premalignant lesions
Cryotherapy 27 (73) 21 (72)
LEEP 21 (57) 17 (59)
Conization 12 (32) 10 (34)
Malignant lesions
Radical or extended hysterectomy 18 (49) 16 (55)
Chemotherapy 9 (24) 10 (34)
Radiation therapy 5 (14) 5 (17)
Data are presented as n (%)
VIA indicates visual inspection with acetic acid; VILI, visual inspection
with Lugol solution; HPV, human papilloma virus DNA test; LEEP, loop
electrosurgical excision procedure.
aSites may report more than 1 screening and treatment method.
bSites may be included in both women with HIV infection and without
HIV infection columns if sites report screening and treatment programs re-
gardless of HIV status.
Journal of Lower Genital Tract Disease • Volume 20, Number 1, January 2016 SSA Cervical Cancer Prevention CapacityMost sites with several cervical cancer screening methods
available performed VIA; however, many sites continue to offer
Pap testing. Ideally, abnormal Pap tests are managed using colpos-
copy and biopsy, if needed, but most of these sites did not have an
available colposcope or pathology services. A recent quality as-
surance program for cervical cytology and histology showed that
an education program for pathologists in resource-constrained set-
tings can lead to improved diagnostic interpretations.17 However,
studies have shown that there is a shortage of pathologists in SSA,
which contributes to the long interval between biopsy results and
treatment.18 Scale-up of Pap testing for many millions of women
would likely create a large burden on the scant pathology services
in much of SSA. In addition, the complexity of Pap testing pro-
grams may increase the proportion of patients who do not return
for treatment because multiple visits are usually necessary, which
requires reliable communication with and transportation for pa-
tients. Khozaim et al.19 reported that loss to follow-up is one of
the major challenges of cervical cancer prevention programs be-
cause a third of their patients in Western Kenyan did not return
for treatment. Currently, a better approach is the single-visit
“screen-and-treat” strategy that uses visual inspection techniques,
followed by cryotherapy for eligible women. However, future
availability of lower-cost, point-of-care rapid hrHPV DNA testing
should also be incorporated into the screen-and-treat strategy to
improve specificity and better identify the women with premalig-
nant lesions who could benefit most from immediate treatment.20
High-risk HPV testing has not been widely available to date, but a
new point-of-care cartridge-based molecular diagnostic system
for hrHPV is now available in SSA that requires very little labora-
tory infrastructure and provides results in 1 hour allowing for
same-day test-and-treat approaches.21 These single-visit approaches© 2015, American Society for Colposcopy and Cervical Pathology
Copyright © 2015 American Society for Colposcopy and Cervical Pdecrease barriers to care, are affordable, and are sustainable, as
opposed to Pap testing and colposcopy.9–11,22–24
In addition to screening, a successful cervical cancer preven-
tion program requires treatment of premalignant lesions. Cryo-
therapy has been shown to be an effective treatment modality,
regardless of HIV status, but has higher subsequent disease nega-
tive rates among women without HIV infection.25 In women with
HIV infection, premalignant lesions tend to be larger and involve
the endocervical canal, which makes it more likely that an addi-
tional treatment method, for example, LEEPor cold-knife cone bi-
opsy, is needed.6,26 Although we found that most sites that offered
treatment for premalignant lesions had cryotherapy, almost a quar-
ter of these sites did not have excisional procedures such as LEEP
available although the sites provided care to women with HIV in-
fection. Cervical cancer prevention sites should increase access
to excisional procedures, either on-site or by referral, which will
involve additional training for providers and implementation of
safety and quality control measures.
Integral to cervical cancer screening programs are the skilled
providers. Our survey showed that physicians performed screen-
ing at a large number of sites. However, it has been shown that
nurses can successfully perform these tasks. In Zambia, which
reportedly has one of the highest mortality rates from cervical can-
cer worldwide, 1 program employs trained nurses to provide dig-
ital cervicography-aided VIA with same-day cryotherapy.27
Digital images of suspicious lesions are reviewed in real time by
gynecologists at remote tertiary care sites. Even among women
with HIV infection, the sensitivity of cervicography-aided VIA
to detect CIN 2/3 lesions was higher than Pap testing.28 Thus, task
shifting from physicians- to nurse-led programs can lower costs
and expand access without compromising effectiveness.
Furthermore, a successful cervical cancer prevention pro-
gram requires treatment of malignant lesions; however, the man-
agement of ICC is a major challenge in SSA countries because
of the lack of access to and varied quality of cancer treatment cen-
ters. In our survey, fewer than half of sites were able to perform
radical or extended hysterectomies and an overwhelming majority
did not have chemotherapy or radiation therapy. An even smaller
proportion had all 3 options available. A 2008 review on cancer
treatment in SSA noted that radiotherapy was available in only
23 of 53 countries and that although there was a 30% increase in
sites during the previous decade, this expansion occurred in coun-
tries already able to offer radiotherapy and was not expanded to
countries that did not have any access to radiation.29 To decrease
ICC deaths, adequate and appropriate treatment options must be
expanded, with special attention to those countries that did not
have any access previously.
Our study has limitations. First, there may have been sam-
pling bias. The survey was sent only to NIH-funded HIV/AIDS
sites, which may have impacted the responses. For example, the
high proportion of sites that offered Pap testing might be because
US investigators, who are accustomed to using the Pap test as the
primary screening method, led these sites. In addition, more than a
third of sites that were invited to participate in the study did not re-
spond. Besides geographic location, we do not have any additional
details about these nonresponding sites. It is possible that sites
without cervical cancer screening did not respond, which would
decrease our reported percentages of sites with on-site screening
availability. Second, we did not queryMinistries of Health, the pri-
vate sector, or other organizations that might have robust cervical
cancer prevention programs. Therefore, our results may not be in-
dicative of the country's response to cervical cancer screening and
may not reflect the general environment. However, more than half
of our respondents were a part of the IeDEA network, which col-
lects data from routine HIV clinical visits and thus provides some35
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there might be misclassification. For example, on-site screening
services might have been interpreted literally, meaning it is possi-
ble that a site could have reported not having on-site screening ser-
vices; however, another building on-campus might have screening
services. Last, SSA is undergoing scale-up of cervical cancer
screening services and our results represent status through the
end of 2013.
Overall, the higher incidence andmortality of cervical cancer
in developing countries can be attributed to a generalized lack of
awareness, absence or poor quality of screening programs, and
poor access to care, prevention and treatment. Building upon the
existing infrastructure in established care delivery systems in
resource-constrained settings represents an ideal framework for
implementing a program to reduce cervical cancer incidence. Al-
though we surveyed HIV programs, it is important to note that
routine cervical cancer screening among the general population
in many countries typically was introduced by HIV clinics. Cost
containment and skilled staff who are able to perform screening
and treatment are integral to the sustainability of a cervical cancer
prevention program. It is possible that a coordinated network can
be established that could serve as a platform to accelerate the
implementation of evidence-based cancer prevention programs
for women with HIV infection and without HIV infection. There
should be a collective effort among public, private, and academic
sectors to increase screening and treatment programs, determine
the most effective screening algorithm, particularly for women
with HIV infection, and conduct cancer research to halt the
projected rise of ICC in resource-constrained settings.
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